Darolutamide Biochemical Recurrence Study
Research payments
$414,604
Through program year 2023, $414,604 in research payments was reported against Darolutamide Biochemical Recurrence Study, across 28 payments, paid by Bayer HealthCare Pharmaceuticals Inc..
- Paid by
- Bayer HealthCare Pharmaceuticals Inc.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
1 row| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2023 | Research | $414,604 | 28 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Lester Borden Greensboro, NC Named on 9 payments
- Frank Cackowski Ann Arbor, MI Named on 2 payments
- Luke Nordquist Omaha, NE Named on 2 payments
- Aaron Katz Garden City, NY Named on 2 payments
- Kenneth Belkoff Tucson, AZ Named on 2 payments
- Jay Page Sandy, UT Named on 2 payments
- Ronald Tutrone Baltimore, MD Named on 1 payment
- Neal Shore Myrtle Beach, SC Named on 1 payment
- Arnold Cinman Los Angeles, CA Named on 1 payment
- Stephen Dyar Greenville, SC Named on 1 payment
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.